Aberrant activation of CDK5 is involved in the pathogenesis of OPIDN

Journal of Neurochemistry

Volumn 99, Issue 1, 2006, Pages 186-197

  Wang, Ying Peng ^a,b,c   Mou, Dan Lei ^d,e   Song, Jun Feng ^a,f   Rao, Zhi Ren ^a   Li, Duan ^a   Ju, Gong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^c Xi'an Gaoxin Hospital   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f NORTHWESTERN POLYTECHNICAL UNIVERSITY   (China)

Author keywords

Cyclin dependent kinase 5; Electron microscopy; Horseradish peroxidase tetramethylbenzidine; Organophosphate induced delayed neuropathy; Triorthocresyl phosphate; Western blot

Indexed keywords

CYCLIN DEPENDENT KINASE 5; ORGANOPHOSPHATE; PROTEIN P25; PROTEIN P35; ROSCOVITINE; TRI ORTHO CRESYL PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; EXPOSURE; HEN; IMMUNOHISTOCHEMISTRY; LUMBAR SPINAL CORD; NERVE CELL; NERVE FIBER TRANSPORT; NEUROPATHY; NEUROTOXICITY; NONHUMAN; ORGANOPHOSPHATE INDUCED DELAYED NEUROPATHY; PATHOGENESIS; PERONEUS NERVE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SPINAL CORD; TISSUE DISTRIBUTION; WESTERN BLOTTING;

ANIMALS; CHICKENS; CYCLIN-DEPENDENT KINASE 5; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FEMALE; HORSERADISH PEROXIDASE; IMMUNOHISTOCHEMISTRY; NERVOUS SYSTEM DISEASES; TRITOLYL PHOSPHATES;

ARMORACIA RUSTICANA;

EID: 33748692399     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.04027.x     Document Type: Article

References (35)

1. Abou-Donia M. B. (1993) The cytoskeletons as a target for organophosphorus ester-induced delayed neurotoxicity (OPIDN). Chem. Biol. Interacts 87, 383-393.
2. Abou-Donia M. B. (1995) Organophosphorus pesticides. In: Handbook of Neurotoxicology (Chang, L. W. and. Dyer, R. S., eds), pp. 419-474. Mercel Dekker, Inc., New York.
3. Abou-Donia M. B. and. Lapadula D. M. (1990) Mechanisms of organophosphorus ester-induced delayed neurotoxicity: type I and type II. Annu. Rev. Pharmacol. Toxicol. 30, 405-440.
4. Akassoglou K., Malester B., Xu J. X., Tessarollo L., Rosenbluth J. and Chao M. V. (2004) Brain-specific deletion of neuropathy target esterase/swisscheese results in neurodegeneration. Proc. Natl Acad. Sci. USA 101, 5075-5080.
5. Barrett D. S. and Oeheme F. W. and. Kruckenberg S. M. (1985) The review organophosphorus ester-induced delayed neurotoxicity. Vet. Hum. Toxicol. 27, 22-37.
6. Bouldin T. W. and Cavanagh J. B. (1979) Organophosphorus neuropathy. Part I: a teased fibre study of the spatio-temporal spread of axonal degeneration. Am. J. Pathol 94, 241-252.
7. Carrington C. D., Lapadula D. M. and Abou-Donia M. B. (1989) Acceleration of anterograde axonal transport in cat sciatic nerve by diisopropyl phosphorofluoridate. Brain Res. 476, 179-182.
8. Cavanagh J. B. (1954) The toxic effects of tri-ortho-cresyl phosphate on the nervous system: an experimental study in hens. J. Neurol. Neurosurg. Psychiat 17, 163-172.
9. Cruz J. C., Tseng H. C., Goldman J. A., Shih H. and Tsai L. H. (2003) Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40, 471-483.
10. Dhavan R. and Tsai L. H. (2001) A decade of CDK5. Nat Rev. Mol Cell Biol. 2, 749-759.
11. George E. B., Glass J. D. and Griffin J. W. (1995) Axotomy induced axonal degeneration is mediated by calcium influx through ion-specific channels. J. Neuroscience 15, 6445-6452.
12. Glynn P. (2000) Neural development and neurodegeneration: two faces of Neuropathy Target Esterase. Prog. Neurobio 61, 61-74.
13. Glynn P. (2003) NTE: one target protein for different toxic syndromes with distinct mechanisms. Bioessays 25, 742-745.
14. Gong X., Tang X., Wiedmann M., Wang X., Peng J., Zheng D., Blair L. A., Marshall J. and Mao Z. (2003) Cdk5-mediated inhibition of the protective effects of transcription factor MEF2 in neurotoxicity-induced apoptosis. Neuron 38, 33-46.
15. Gupta R. P., Abdel-Rahman A. and Wilmarth K. W. and. Abou-Donia M. B. (1997) Alteration in neurofilament axonal transport in the sciatic nerve of the diisopropyl phosphorofluoridate (DFP)-treated hen. Biochem. Pharmacol. 53, 1799-1806.
16. Gupta R. P. and Abou-Donia M. B. (1994) In vivo and in vitro effects of diisopropyl phosphorofluoridate (DFP) on the rate of hen brain tubulin polymerization. Neurochem. Res. 19, 435-444.
17. Jamal G. A. (1997) Neurological syndromes of organophosphorus compounds Adeverse. Drug. React. Toxicol. Rev. 16, 133-170.
18. Johnson M. K. (1982) The target for initiation of delayed neurotoxicity by organophosphorus esters: biochemical studies and toxicological applications. Rev. Biochem. Toxicol. 4, 141-212.
19. Kerokoski P., Suuronen T., Salminen A. and Soininen H. and. Pirttila T. (2004) Both N-methyl-d-aspartate (NMDA) and non-NMDA receptors mediate glutamate-induced cleavage of the cyclin-dependent kinase 5 (cdk5) activator p35 in cultured rat hippocampal neurons. Neurosci. Lett. 368, 181-185.
20. Kretzchmar D., Hasan G., Sharma S., Heisenberg M. and Benzer S. (1997) The swiss cheese mutant cause glial hyperwraping and brain degeneration in Drosophila. J. Neurosci. 17, 7425-7432.
21. Le Vay S., Meier C. and Glees P. (1971) Effects of tri-ortho-cresyl phosphate on spinal ganglia and peripheral nerves of chicken. Acta Neuropath 17, 103-113.
22. Lotti M. (1991) The pathogenesis of organophosphate polyneuropathy. Crit. Rev. Toxicol. 21, 465-487.
23. Lu K. R., Zhang S. L. and Zhang Z. M. (1992) Clinical observation on outbreak of Tri-ortho-cresyl phosphate (TOCP) poisoning. J. Hygiene Res. 21, 268-271.
24. Luo P. and. Dessem D. (1999) Ultrastructure anatomy of physiological identified jaw-muscle spindle afferent terminations onto retrogradely labeled jaw-elevator motoneurons in the rat. J. Comp. Neurol. 406, 384-401.
25. Moretto A., Lotti M. and Sabri M. I. and. Spencer P. S. (1987) Progressive deficit of retrograde axonal transport is associated with the pathogenesis of di-n-butyl dichlorvos axonopathy. J. Neurochem. 49, 1515-1522.
26. Nikolic M., Chou M. M., Lu W., Mayer B. J. and Tsai L. H. (1998) The p35/Cdk5 kinase is a neuron-specific Rac effector that inhibits Pak1 activity. Nature 395, 194-198.
27. Nikolic M., Dudek H., Kwon Y. T., Ramos Y. F. and Tsai L. H. (1996) The Cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes Dev. 10, 816-825.
28. Patrick G. N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P. and Tsai L. H. (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402, 615-622.
29. Ratner N., Bloom G. S. and Brady S. T. (1998) A role for cyclin-dependent kinase (s) in the modulation of fast anterograde axonal transport: effects defined byolomoucine and the APC tumor suppressor protein. J. Neurosci. 18, 7717-7726.
30. Schwab B. W. and. Richardson R. J. (1984) Lymphocyte and brain neurotoxic esterase: Dose and time dependence of inhibition in the hen examined with three organophosphorus esters. Toxicol. Appl. Pharmacol. 83, 1-9.
31. Sharma P., Sharma M., Amin N. D., Albers R. W. and Pant H. C. (1999) Regulation of cyclin-dependent kinase 5 catalytic activity by phosphorylation. Proc. Natl Acad. Sci. USA 96, 11 156-11 160.
32. Smith D. S. and Tsai L. H. (2002) Cdk5 behind the wheel: a role in trafficking and transport. Trends Cell Biol. 12, 28-36.
33. Tsai L. H., Delalle I., Caviness V. S., Chae T. Jr and Harlow E. (1994) p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371, 419-423.
34. Winrow C. J., Hemming M. L., Allen D. M., Quistad G. B., Casida J. E. and Barlow C. (2003) Loss of neuropathy target esterase in mice links organophosphate exposure to hyperactivity. Nat Genet 33, 477-485.
35. Xie K., Gupta R. P. and Abou-Donia M. B. (2002) Protein levels of neurofilament subunits in the hen central nervous system following prevention and potentiation of diisopropyl phosphorofluoride (DFP) induced delayed neurotoxicity. Biochem. Pharmacol. 63, 11-19.